HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 08, 2024 16:30 ET
|
HOOKIPA Pharma Inc.
New Leadership Appointments; Positive Clinical and Regulatory Reports for the Lead Product Candidate, HB-200 (eseba-vec); On track to initiate the Phase 2/3 “AVALON-1” study with eseba-vec in Q4 2024 ...
HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split
July 08, 2024 07:01 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, July 08, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...
HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
June 04, 2024 13:00 ET
|
HOOKIPA Pharma Inc.
Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumabIn a subset of 17 evaluable patients with...
HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting
May 23, 2024 17:01 ET
|
HOOKIPA Pharma Inc.
HOOKIPA to present an oral abstract at the American Society for Clinical Oncology (ASCO) 2024 Annual Meeting on June 4Updated data of HB-200 plus pembrolizumab demonstrate a favorable safety profile...
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 09, 2024 07:01 ET
|
HOOKIPA Pharma Inc.
Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligns with U.S. Food and...
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
April 24, 2024 07:01 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, April 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
April 10, 2024 07:01 ET
|
HOOKIPA Pharma Inc.
HOOKIPA announces alignment with FDA on pivotal trial design and protocol for HB-200 in combination with pembrolizumabHB-200 program receives Priority Medicines (PRIME) designation from EMA NEW YORK...
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
March 22, 2024 07:01 ET
|
HOOKIPA Pharma Inc.
Best-in-class preliminary Phase 2 data for HB-200 in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancers in the first line setting Expect updated Phase 2...
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
March 06, 2024 07:01 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, March 06, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
December 21, 2023 07:01 ET
|
HOOKIPA Pharma Inc.
Gilead purchased 15 million newly issued shares of common stock at a price of $1.4167 per shareFollowing the close of the transaction on December 20, 2023, Gilead holds 19.4% of HOOKIPA’s outstanding...